A brand-new technology of cross-linked hyaluronic acid in powder form for ophthalmic use, overcoming problems related to the loss of stability of low-dose linear hyaluronic acid. This technology improves the performance of ophthalmic drops used for dry eye syndrome, for contact lens wearers and for lubrication of the ocular surface after surgery.

Bioitech is currently expanding its range of innovative cross-linked raw materials in collaboration with companies working in the pharmaceutical sector.

An innovative extraction system for mucilage combined with a stabilization process for the production of gels that are completely free of added substances and / or thickeners, for use in various areas of medicine such as ophthalmology and cosmetics.

In 2012, Bioitech was the first company to produce an injectable filler based on cross-linked carboxymethylcellulose for aesthetic use. This filler, completely free from protein residues and bacterial endotoxins, provides many safety advantages compared to common hyaluronic acids. The product represents an absolute innovation to date and the future of dermal fillers for aesthetic use thanks to its biotechnological and anti-aging characteristics.

The know-how achieved with the manufacture of carboxymethylcellulose-based fillers enabled Bioitech to develop a new generation of crosslinked hyaluronic acids in 2019, for dermatological and aesthetic use.

In 2020, Bioitech was pleased to announce the commercializationof a series of oral products completely free from preservatives. In accordance with FDA and EMA warnings, the products effectively solve problems regarding the use of products containing benzoates for infants and children.

A new project aimed at creating a cosmetic line whose products will be sterile and totally free of excipients and preservatives, with active ingredients absolutely proven for efficacy and safety.

Bioitech has developed a chemically cross-linked platform that is completely purified of residual reactants, able to function as a network for the transdermal delivery of pharmacological substances. Collaboration with pharmaceutical companies is experimental, aimed at the future of trans dermal administration of substances such as insulin for diabetic patients and hormones for endocrine altered states.